{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:50:54Z","timestamp":1781650254998,"version":"3.54.5"},"reference-count":15,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2017,12,18]]},"abstract":"<jats:p>Clinically amyopathic dermatomyositis (CADM) is a rare entity that presents with cutaneous manifestations of classic dermatomyositis but without muscle weakness or abnormal muscle enzymes. It is more common in young white and Asian females. A subset of patients with CADM has a specific antibody known as anti-MDA5. These patients have a more aggressive course with distinct cutaneous features, pulmonary involvement and early death. Here, we present the case of a 64-year-old Caucasian male with no significant medical history who was admitted with marked weight loss and a painful rash for 6\u2009months. Patient had no muscle weakness and his rash was characteristic of classic dermatomyositis. Skin biopsy was suggestive of dermatomyositis but muscle enzymes were normal. His serum was positive for anti-MDA5 antibody. Extensive workup failed to detect any malignancy but he did show non-specific interstitial pneumonia. He was treated with prednisone and mycophenolate with good clinical response.<\/jats:p>","DOI":"10.1136\/bcr-2017-222060","type":"journal-article","created":{"date-parts":[[2018,1,4]],"date-time":"2018-01-04T04:35:09Z","timestamp":1515040509000},"page":"bcr-2017-222060","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Clinically amyopathic dermatomyositis associated with anti-MDA5 antibody"],"prefix":"10.1136","volume":"2018","author":[{"given":"Konstantinos","family":"Parperis","sequence":"first","affiliation":[{"name":"Department of Medicine, Maricopa Medical Center and University of Arizona College of Medicine, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirali","family":"Kiyani","sequence":"additional","affiliation":[{"name":"Internal Medicine, Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,1,4]]},"reference":[{"key":"2025082707225510000_2018.jan03_3.bcr-2017-222060.1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s10067-016-3443-2","article-title":"Mycophenolate mofetil for the patients with interstitial lung diseases in amyopathic dermatomyositis with anti-MDA-5 antibodies","volume":"36","author":"Hayashi","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2025082707225510000_2018.jan03_3.bcr-2017-222060.2","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2025082707225510000_2018.jan03_3.bcr-2017-222060.3","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/0190-9622(91)70153-S","article-title":"Amyopathic dermatomyositis (dermatomyositis sin\u00e9 myositis). Presentation of six new cases and review of the literature","volume":"24","author":"Euwer","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"2025082707225510000_2018.jan03_3.bcr-2017-222060.4","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32833f1987"},{"key":"2025082707225510000_2018.jan03_3.bcr-2017-222060.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.21023"},{"key":"2025082707225510000_2018.jan03_3.bcr-2017-222060.6","doi-asserted-by":"publisher","DOI":"10.1002\/art.24621"},{"key":"2025082707225510000_2018.jan03_3.bcr-2017-222060.7","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20464"},{"key":"2025082707225510000_2018.jan03_3.bcr-2017-222060.8","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21728"},{"key":"2025082707225510000_2018.jan03_3.bcr-2017-222060.9","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21992"},{"key":"2025082707225510000_2018.jan03_3.bcr-2017-222060.10","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker518"},{"key":"2025082707225510000_2018.jan03_3.bcr-2017-222060.11","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/350195"},{"key":"2025082707225510000_2018.jan03_3.bcr-2017-222060.12","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40257-016-0199-z","article-title":"Amyopathic dermatomyositis: a concise review of clinical manifestations and associated malignancies","volume":"17","author":"Udkoff","year":"2016","journal-title":"Am J Clin Dermatol"},{"key":"2025082707225510000_2018.jan03_3.bcr-2017-222060.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205278"},{"key":"2025082707225510000_2018.jan03_3.bcr-2017-222060.14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel112"},{"key":"2025082707225510000_2018.jan03_3.bcr-2017-222060.15","doi-asserted-by":"publisher","DOI":"10.1378\/chest.13-0186"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2017-222060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T14:23:02Z","timestamp":1756304582000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2017-222060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,4]]},"references-count":15,"alternative-id":["10.1136\/bcr-2017-222060"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2017-222060","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,4]]}}}